Literature DB >> 8314006

Cellular engineering and gene therapy strategies for insulin replacement in diabetes.

C B Newgard1.   

Abstract

In diabetes, insulin secretion is either completely absent (insulin-dependent diabetes mellitus [IDDM]) or inappropriately regulated (non-insulin-dependent diabetes mellitus [NIDDM]). In recent years, new insights into the molecular and biochemical mechanism(s) of fuel-mediated insulin release coupled with advances in gene transfer technology have led to the investigation of molecular strategies for replacement of normal insulin delivery function. Such initiatives have included attempts to engineer glucose-stimulated insulin secretion in cell lines that might serve as surrogates for islets in IDDM. The development of DNA virus gene transfer systems of remarkable efficiency also has suggested ways in which the beta-cell dysfunction of NIDDM might ultimately be repaired by gene therapy. The emerging work in these areas and implications for the future are summarized in this perspective.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8314006     DOI: 10.2337/diab.43.3.341

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells.

Authors:  H Heimberg; A De Vos; K Moens; E Quartier; L Bouwens; D Pipeleers; E Van Schaftingen; O Madsen; F Schuit
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  [Insulin producing cells as therapy in diabetes mellitus].

Authors:  W J Schnedl; H E Hohmeier; C B Newgard
Journal:  Naturwissenschaften       Date:  1996-01

3.  Insulin gene transfer enhances the function of human islet grafts.

Authors:  S Deng; M Vatamaniuk; M-M Lian; N Doliba; J Wang; E Bell; B Wolf; S Raper; F M Matschinsky; J F Markmann
Journal:  Diabetologia       Date:  2003-03-07       Impact factor: 10.122

4.  Glucose-responsive gene delivery in pancreatic Islet cells via recombinant adeno-associated viral vectors.

Authors:  Y W Yang; R M Kotin
Journal:  Pharm Res       Date:  2000-09       Impact factor: 4.200

5.  Combinatorial insulin secretion dynamics of recombinant hepatic and enteroendocrine cells.

Authors:  Kiranmai Durvasula; Peter M Thulé; Athanassios Sambanis
Journal:  Biotechnol Bioeng       Date:  2011-11-21       Impact factor: 4.530

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

7.  Glucose-modulated transgene expression via recombinant adeno-associated virus.

Authors:  Ya-Wun Yang; Yuan-Chiao Hsieh; Chih-Kai Chao
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

8.  Glucagon secretion and signaling in the development of diabetes.

Authors:  Herbert Y Gaisano; Patrick E Macdonald; Mladen Vranic
Journal:  Front Physiol       Date:  2012-09-04       Impact factor: 4.566

9.  Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells.

Authors:  Janet Lawandi; Chang Tao; Binhai Ren; Paul Williams; Dora Ling; M Anne Swan; Najah T Nassif; Fraser R Torpy; Bronwyn A O'Brien; Ann M Simpson
Journal:  Mol Ther Methods Clin Dev       Date:  2015-04-08       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.